You are here

Survey: One Third of Physicians Recommend E-Cigarettes for Smoking Cessation

FDA has yet to weigh in

Physicians are increasingly discussing and recommending electronic cigarettes (e-cigarettes) as smoking-cessation devices for their patients, but more research needs to be done on the efficacy and safety of these products, according to a new survey of North Carolina physicians published in PLOS One.

The study is believed to be the first to measure attitudes toward e-cigarettes among physicians treating adult smokers.

“Even in the absence of evidence regarding the health impact of e-cigarettes and other vaping devices, a third of physicians we surveyed are recommending e-cigarettes to their patients to help quit smoking,” said co-author Leah Ranney, PhD. “Yet, e-cigarettes are not approved by the FDA for smoking cessation. It is clear that physicians should refrain from recommending e-cigarettes until more is known about their safety.”

The study found that physicians were more likely to recommend e-cigarettes when their patients asked about them or when the physician believed e-cigarettes were safer than smoking standard cigarettes. However, physicians often have inconsistent information about the safety of using e-cigarettes, and in this survey 13% were unaware that e-cigarettes are not approved by the FDA.

“Physicians may choose to use FDA-approved medications rather than devices and products not approved by the FDA,” said co-author Dr. Adam Goldstein.

The surveyed involved a random sample of 128 North Carolina physicians. Two thirds (67%) of this group indicated that e-cigarettes are a helpful aid for smoking cessation, and 35% recommended them to their patients.

Source: University of North Carolina; July 30, 2014.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs